medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2023, Number 1

<< Back Next >>

Rev Latin Infect Pediatr 2023; 36 (1)

Carbapenem-resistant Acinetobacter baumannii in pediatric population: epidemiological overview

Castillo BJI, Casillas VN, Llaca DJ, Mascareñas SA

Language: Spanish
References: 41
Page: 42-46
PDF size: 187.38 Kb.


ABSTRACT

Acinetobacter baumannii has emerged as a threat to humanity due to the high prevalence of multidrug-resistant strains. This pathogen intrinsically produces β-lactamases, which confer resistance to some cephalosporins and can acquire novel resistance genes for carbapenemics. In addition to the blaOXA-51 family present in A. baumannii, six enzyme subgroups have been reported in Latin America and the Caribbean. Currently, there are regional variations in the distribution of the molecular characteristics of these enzymes. The article reviews the literature with emphasis on the molecular epidemiology of carbapenem resistance in this microorganism.


REFERENCES

  1. Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB et al. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017; 7: 55.

  2. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006; 12 (9): 826-836.

  3. Cisneros JM, Pachón J. Acinetobacter baumannii: un patógeno nosocomial de difícil control. Enferm Infecc Microbiol Clin. 2003; 21 (5): 221-223.

  4. Mammina C, Palma DM, Bonura C, Aleo A, Fasciana T, Sodano C et al. Epidemiology and clonality of carbapenem-resistant Acinetobacter baumannii from an intensive care unit in Palermo, Italy. BMC Res Notes. 2012; 5: 365.

  5. Clark NM, Zhanel GG, Lynch JP. Emergence of antimicrobial resistance among Acinetobacter species: a global threat. Curr Opin Crit Care. 2016; 22 (5): 491-499.

  6. CDC. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.

  7. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: World Health Organization; 2017 (WHO/EMP/IAU/2017.12). Licence: CC BY-NC-SA 3.0 IGO.

  8. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual epidemiological report 2021. Stockholm: ECDC; 2022.

  9. Gajic I, Jovicevic M, Milic M, Kekic D, Opavski N, Zrnic Z et al. Clinical and molecular characteristics of OXA-72-producing Acinetobacter baumannii ST636 outbreak at a neonatal intensive care unit in Serbia. J Hosp Infect. 2021; 112: 54-60.

  10. Konca C, Tekin M, Geyik M. Susceptibility patterns of multidrug-resistant Acinetobacter baumannii. Indian J Pediatr. 2021; 88 (2): 120-126.

  11. Logan L, Gandra S, Trett A, Weinstein R, Laxminarayan R. Acinetobacter baumannii resistance trends in children in the United States, 1999-2012. J Pediatric Infect Dis Soc. 2019; 8 (2): 136-142.

  12. Cerezales M, Ocampo-Sosa AA, Álvarez Montes L, Díaz Ríos C, Bustamante Z, Santos J et al. High prevalence of extensively drug-resistant Acinetobacter baumannii at a children hospital in Bolivia. Pediatr Infect Dis J. 2018; 37 (11): 1118-1123.

  13. Rossi I, Royer S, Ferreira ML, Campos PA, Fuga B, Melo GN et al. Incidence of infections caused by carbapenem-resistant Acinetobacter baumannii. Am J Infect Control. 2019; 47 (12): 1431-1435.

  14. European Centre for Disease Prevention and Control. Carbapenem-resistant Acinetobacter baumannii in healthcare settings - 8 December 2016. Stockholm: ECDC; 2016.

  15. Romanin P, Palermo RL, Cavalini JF, Fávaro LDS, De Paula-Petroli SB, Fernandes EV et al. Multidrug-and extensively drug-resistant Acinetobacter baumannii in a tertiary hospital from Brazil- and importance of carbapenemase encoding genes and epidemic clonal complexes in a 10-year study. Microb Drug Resist. 2019; 25 (9): 1365-1373.

  16. Dias VC, Diniz CG, Peter AC, Bastos AN, Bastos VQ, Bastos LQ et al. Epidemiological characteristics and antimicrobial susceptibility among carbapenem-resistant non-fermenting bacteria in Brazil. J Infect Dev Ctries. 2016; 10 (6): 544-553.

  17. Neves FC, Clemente WT, Lincopan N, Paiao ID, Neves PR, Romanelli RM et al. Clinical and microbiological characteristics of OXA-23- and OXA-143-producing Acinetobacter baumannii in ICU patients at a teaching hospital, Brazil. Braz J Infect Dis. 2016; 20 (6): 556-563.

  18. Camargo CH, Yamada AY, Nagamori FO, de Souza AR, Tiba-Casas MR, de Moraes Franca FA et al. Clonal spread of ArmA- and OXA-23-coproducing Acinetobacter baumannii International clone 2 in Brazil during the first wave of the COVID-19 pandemic. J Med Microbiol. 2022; 71 (4).

  19. Garza-González E, Morfín-Otero R, Mendoza-Olazarán S, Bocanegra-Ibarias P, Flores-Treviño S, Rodríguez-Noriega E et al. A snapshot of antimicrobial resistance in Mexico. Results from 47 centers from 20 states during a six-month period. PLoS One. 2019; 14 (3): e0209865.

  20. Morfin-Otero R, Alcántar-Curiel MD, Rocha MJ, Alpuche-Aranda CM, Santos-Preciado JI, Gayosso-Vázquez C et al. Acinetobacter baumannii infections in a tertiary care Hospital in Mexico over the past 13 years. Chemotherapy. 2013; 59 (1): 57-65.

  21. Bello-López E, Rocha-Gracia RDC, Castro-Jaimes S, Cevallos MA, Vargas-Cruz M, Verdugo-Yocupicio R et al. Antibiotic resistance mechanisms in Acinetobacter spp. strains isolated from patients in a paediatric hospital in Mexico. J Glob Antimicrob Resist. 2020; 23: 120-129.

  22. Marchaim D, Levit D, Zigron R, Gordon M, Lazarovitch T, Carrico JA et al. Clinical and molecular epidemiology of Acinetobacter baumannii bloodstream infections in an endemic setting. Future Microbiol. 2017; 12 (4): 271-283.

  23. Escandón-Vargas K, Reyes S, Gutiérrez S, Villegas MV. The epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti Infect Ther. 2017; 15 (3): 277-297.

  24. Lee Y, Kim YR, Kim J, Park YJ, Song W, Shin JH et al. Increasing prevalence of blaOXA-23-carrying Acinetobacter baumannii and the emergence of blaOXA-182-carrying Acinetobacter nosocomialis in Korea. Diagn Microbiol Infect Dis. 2013; 77 (2): 160-163.

  25. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis. 2000; 31 (3): 690-697.

  26. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006; 27: 351-353.

  27. Scaife W, Young HK, Paton RH, Amyes SG. Transferable imipenem-resistance in Acinetobacter species from a clinical source. J Antimicrob Chemother. 1995; 36: 585-586.

  28. Donald HM, Scaife W, Amyes SG, Young HK. Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother. 2000; 44: 196-199.

  29. Goic-Barisic I, Kovacic A, Medic D, Jakovac S, Petrovic T, Tonkic M et al. Endemicity of OXA-23 and OXA-72 in clinical isolates of Acinetobacter baumannii from three neighbouring countries in Southeast Europe. J Appl Genet. 2021; 62 (2): 353-359.

  30. Merkier AK, Catalano M, Ramirez MS, Quiroga C, Orman B, Ratier L et al. Polyclonal spread of blaOXA-23 and blaOXA-58 in Acinetobacter baumannii isolates from Argentina. J Infect Dev Ctries. 2008; 2: 235-240.

  31. Bocanegra-Ibarias P, Peña-López C, Camacho-Ortiz A, Llaca-Díaz J, Silva-Sánchez J, Barrios H et al. Genetic characterisation of drug resistance and clonal dynamics of Acinetobacter baumannii in a hospital setting in Mexico. Int J Antimicrob Agents. 2015; 45 (3): 309-313.

  32. Alcántar-Curiel MD, García-Torres LF, González-Chávez MI, Morfín-Otero R, Gayosso-Vázquez C, Jarillo-Quijada MD et al. Molecular mechanisms associated with nosocomial carbapenem-resistant Acinetobacter baumannii in Mexico. Arch Med Res. 2014; 45 (7): 553-560.

  33. Lukic-Grlic A, Kos M, Zizek M, Luxner J, Grisold A, Zarfel G et al. Emergence of carbapenem-hydrolyzing oxacillinases in Acinetobacter baumannii in children from croatia. Chemotherapy. 2020; 64 (4): 167-172.

  34. Chen Y, Ai L, Guo P, Huang H, Wu Z, Liang X et al. Molecular characterization of multidrug resistant strains of Acinetobacter baumannii isolated from pediatric intensive care unit in a Chinese tertiary hospital. BMC Infect Dis. 2018; 18 (1): 614.

  35. Nor FM, Shahari AS, Palaniasamy NK, Rustam FRM, M-Zain Z, Lee BPK et al. Multidrug resistant (MDR) Acinetobacter baumannii: rate of occurrence from a tertiary hospital, Malaysia. Int J Infect Dis. 2019; 79 (2019): 46-47.

  36. Hu Z, Wang Z, Liu D, Chen P, Wang H, Chen Y et al. Clinical and molecular microbiological characteristics of carbapenem-resistant Acinetobacter baumannii strains in an NICU. Pediatr Int. 2011; 53 (6): 867-872.

  37. Bello-López E, Castro-Jaimes S, Cevallos MA, Rocha-Gracia RDC, Castañeda-Lucio M, Sáenz Y et al. Resistome and a novel blaNDM-1-harboring plasmid of an Acinetobacter haemolyticus strain from a children's hospital in Puebla, Mexico. Microb Drug Resist. 2019; 25 (7): 1023-1031.

  38. Kostyanev T, Xavier BB, García-Castillo M, Lammens C, Bravo-Ferrer Acosta J, Rodríguez-Baño J et al. Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study. Int J Antimicrob Agents. 2021; 57 (6): 106345.

  39. Lukovic B, Gajic I, Dimkic I, Kekic D, Zornic S, Pozder T et al. The first nationwide multicenter study of Acinetobacter baumannii recovered in Serbia: emergence of OXA-72, OXA-23 and NDM-1-producing isolates. Antimicrob Resist Infect Control. 2020; 9 (1): 101.

  40. Karaaslan A, Soysal A, Altinkanat Gelmez G, Kepenekli Kadayifci E, Soyletir G, Bakir M. Molecular characterization and risk factors for carbapenem-resistant Gram-negative bacilli colonization in children: emergence of NDM-producing Acinetobacter baumannii in a newborn intensive care unit in Turkey. J Hosp Infect. 2016; 92 (1): 67-72.

  41. Alcántar-Curiel MD, Rosales-Reyes R, Jarillo-Quijada MD, Gayosso-Vázquez C, Fernández-Vázquez JL, Toledano-Tableros JE et al. Carbapenem-resistant Acinetobacter baumannii in three tertiary care hospitals in Mexico: virulence profiles, innate immune response and clonal dissemination. Front Microbiol. 2019; 10: 2116.




2020     |     www.medigraphic.com